Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
letter
. 1982 May;13(5):750–752. doi: 10.1111/j.1365-2125.1982.tb01453.x

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

P Dayer, A Kubli, A Kupfer, F Courvoisier, L Balant, J Fabre
PMCID: PMC1402093  PMID: 6123344

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balant L., Dayer P., Fabre J. Polymorphism in drug metabolism. Br Med J. 1978 Nov 4;2(6147):1299–1299. doi: 10.1136/bmj.2.6147.1299-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balant L., Francis R. J., Tozer T. N., Marmy A., Tschopp J. M., Fabre J. Influence of renal failure on the hepatic clearance of bufuralol in man. J Pharmacokinet Biopharm. 1980 Oct;8(5):421–438. doi: 10.1007/BF01059544. [DOI] [PubMed] [Google Scholar]
  3. Balant L., Francis R. J., Tschopp J. M., Tinguely D., Estreicher J., Fabre J. Pharmacocinétique du bufuralol chez l'homme. Pharm Acta Helv. 1978;53(11):307–313. [PubMed] [Google Scholar]
  4. Balant L., Gorgia A., Tschopp J. M., Revillard C., Fabre J. Pharmacocinétique de deux médicaments bêta-bloquants: détection d'une anomalie pharmacogénétique. Schweiz Med Wochenschr. 1976 Oct 9;106(41):1403–1407. [PubMed] [Google Scholar]
  5. Bertilsson L., Dengler H. J., Eichelbaum M., Schulz H. U. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol. 1980 Feb;17(2):153–155. doi: 10.1007/BF00562624. [DOI] [PubMed] [Google Scholar]
  6. Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 1981 Jan;11(1):89–91. doi: 10.1111/j.1365-2125.1981.tb01108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  8. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Francis R. J., East P. B., McLaren S. J., Larman J. Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection. Biomed Mass Spectrom. 1976 Dec;3(6):281–285. doi: 10.1002/bms.1200030606. [DOI] [PubMed] [Google Scholar]
  10. Haefelfinger P. Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1980 Dec 12;221(2):327–335. doi: 10.1016/s0378-4347(00)84318-2. [DOI] [PubMed] [Google Scholar]
  11. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  12. Sloan T. P., Idle J. R., Smith R. L. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther. 1981 Apr;29(4):493–497. doi: 10.1038/clpt.1981.68. [DOI] [PubMed] [Google Scholar]
  13. Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tschopp J. M., Gorgia A., Balant L., Revillard C., Francis R. J., Fabre F. J. Rôle des métabolites dans les relations entre la pharmacocinétique et l'effet des agents beta-bloquants. Expériences avec le tolamolol et le bufuralol. Schweiz Med Wochenschr. 1978 May 20;108(20):756–764. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES